The Technical Analyst
Select Language :
Acer Therapeutics Inc [ACER]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Acer Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Acer Therapeutics Inc is listed at the  Exchange

-17.95% $0.660

America/New_York / 20 nov 2023 @ 15:59


Acer Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 16.15 mill
EPS: -1.930
P/E: -0.342
Earnings Date: Nov 19, 2023
SharesOutstanding: 24.46 mill
Avg Daily Volume: 2.39 mill
RATING 2023-11-20
B-
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Strong Sell
DE: Strong Sell
P/E: Sell
Price To Book: Strong Sell
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.342 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.06x
Company: PE -0.342 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.603 - 0.717

( +/- 8.64%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-11-17 Aselage Steve Sell 483 741 Common Stock, $0.0001 par value per share
2023-11-17 Dunn John Michael Sell 27 380 Common Stock, $0.0001 par value per share
2023-11-17 Joseph Donald Sell 14 285 Common Stock, $0.0001 par value per share
2023-11-17 Schelling Chris Sell 2 712 529 Common Stock, $0.0001 par value per share
2023-11-17 Palmin Harry S Sell 125 000 Common Stock, $0.0001 par value per share
INSIDER POWER
-66.05
Last 96 transactions
Buy: 5 870 002 | Sell: 3 622 222

Forecast: 01:40 - $0.803

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.660 (-17.95% )
Volume 0.575 mill
Avg. Vol. 2.39 mill
% of Avg. Vol 24.07 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Acer Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Acer Therapeutics Inc

RSI

Intraday RSI14 chart for Acer Therapeutics Inc

Last 10 Buy & Sell Signals For ACER

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Acer Therapeutics Inc

ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Last 10 Buy Signals

Date Signal @
RADUSDMar 29 - 08:24$3.39
XVSUSDMar 29 - 08:20$16.04
SAVAXUSDMar 29 - 08:1961.03
RSS3USDMar 29 - 08:190.550
STETHUSDMar 29 - 08:193 528.46
P2PSUSDMar 29 - 08:18202.45
NAKAUSDMar 29 - 08:192.12
MNTUSDMar 29 - 08:191.160
KASUSDMar 29 - 08:200.137
JOEUSDMar 29 - 08:190.872

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.